New drug TQB2102 is included in the breakthrough therapy program
October 14, 2025
Source: drugdu
83
On October 13, Sino Biopharmaceutical (01177) announced that its independently developed Class 1 new drug TQB2102 for injection, a HER2 bispecific antibody-drug conjugate (ADC), has been included in the Breakthrough Therapy Program by the Center for Drug Evaluation of the China National Medical Products Administration for the treatment of HER2 IHC 3+ advanced colorectal cancer that has failed prior treatment with oxaliplatin, irinotecan, or fluorouracil.
https://finance.eastmoney.com/a/202510133532526140.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
